Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 4/20 | 0.40 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.37 |
| ▸ | CDK2 | P24941 | 10/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20740491 | 0.75 | MARK3 (0.40) | MARK3MARK4CCNE1CDK2CDK1 | |
| SCHEMBL22347964 | 0.73 | CDK2 (0.55) | MARK3MARK4CCNE1CDK2CDK1 | |
| SCHEMBL20740490 | 0.70 | MARK3 (0.35) | MARK3MARK4CCNE1CDK2CDK1 | |
| SCHEMBL20740467 | 0.70 | MARK3 (0.35) | MARK3MARK4CCNE1CDK2CDK1 | |
| SCHEMBL19474450 | 0.70 | CDK4 (0.53) | MARK3MARK4CCNE1CDK2CDK1 | |
| SCHEMBL20740437 | 0.69 | CCNE1 (0.35) | MARK3MARK4CCNE1CDK2CDK1 | |
| SCHEMBL11976979 | 0.68 | OPRM1 (0.38) | MARK3CCNE1CDK2ABL1BCR | |
| SCHEMBL28767333 | 0.68 | MARK3 (0.50) | MARK3MARK4CCNE1CDK2 | |
| SCHEMBL11976978 | 0.67 | OPRM1 (0.40) | MARK3MARK4CCNE1CDK2ALDH1A1 | |
| SCHEMBL25091178 | 0.67 | MARK3 (0.40) | MARK3MARK4CCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444254-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | SHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD. (CN) | 2019-03-07 | — | — | US | disclosed |
| EP-3444254-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | Shanghai Xunhe Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CDK4, CDK6, CCNI | MARK3 1349/4885MARK4 1313/4885CCNE1 40/4885 |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | CDK4, CDK6, CCNI | MARK3 1349/4885MARK4 1313/4885CCNE1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.